TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8558217

Group type: EXPERIMENTAL
Intervention: FEC2
Number of subjects: 759

Group type: COMPARATOR
Intervention: CMF2
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: FEC1
Number of subjects: 759

Group type: COMPARATOR
Intervention: CMF1
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: FEC (epirubicin-containing regimen)
Number of subjects: 759
Study: 1829757

Group type: EXPERIMENTAL
Intervention: Ondansetron (OND)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) plus Dexamethasone (DEX)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: OND plus DEX
Number of subjects: 102

Group type: COMPARATOR
Intervention: OND
Number of subjects: 102
Study: 7100223

Group type: EXPERIMENTAL
Intervention: (-)eburnamonine (100 mg infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chronic treatment with (-)eburnamonine (oral route)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 31205166

Group type: EXPERIMENTAL
Intervention: PROMIS health domains
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Health Utility Estimation Equation (HEE) derived from PROMIS domains
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Validation cohort mean health utility
Number of subjects: 439
Study: 29808970

Group type: EXPERIMENTAL
Intervention: Singing groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 0
Study: 26260492

Group type: EXPERIMENTAL
Intervention: Integrated health protection/health promotion group (HP/HP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Health protection-only group (HPO)
Number of subjects: 54
Study: 24787266

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no ischemic preconditioning)
Number of subjects: 100
Study: 22895140

Group type: EXPERIMENTAL
Intervention: Topotecan/cisplatin (TP)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Cisplatin/etoposide (PE)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Topotecan/etoposide (TE)
Number of subjects: 795
Study: 20015193

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Combined Parent Training and Child Treatment (PT+CT)
Number of subjects: 99
Study: 18061705

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 mcg every 3 h
Number of subjects: 228

Group type: COMPARATOR
Intervention: Hypertonic saline and d-cloprostenol 2.5 mg/h
Number of subjects: 228
Study: 14769088

Group type: EXPERIMENTAL
Intervention: Face-to-face communication media
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Telephone communication media
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Computer mediated communication
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Self-ratings and partner ratings
Number of subjects: 400
Study: 11401178

Group type: EXPERIMENTAL
Intervention: Intravenous cilomilast 1, 2, and 4 mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oral cilomilast 15 mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oral cilomilast 15 mg in fed subjects
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oral cilomilast 15 mg in fasted subjects
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oral cilomilast 15 mg with different dosing times
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oral cilomilast 15 mg with aluminum hydroxide‐magnesium hydroxide
Number of subjects: 96
Study: 9566385

Group type: EXPERIMENTAL
Intervention: Estrogen-replacement therapy
Number of subjects: 2816
Study: 7816217

Group type: EXPERIMENTAL
Intervention: Healthy Back Program presentation
Number of subjects: 3430

Group type: COMPARATOR
Intervention: Control (no presentation)
Number of subjects: 3430
Study: 3190163

Group type: EXPERIMENTAL
Intervention: Moderate dose of vitamin C (200 mg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High dose of vitamin C (2,000 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 1230395

Group type: EXPERIMENTAL
Intervention: Medical hypnosis in group suggestive sessions and self-induced trance states
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group receiving standard haematologic care
Number of subjects: 20
Study: 31701549

Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percentile-based bootstrap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal bootstrap
Number of subjects: 0
Study: 29273116

Group type: EXPERIMENTAL
Intervention: Economic intervention integrated with family coaching
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Economic intervention alone
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control
Number of subjects: 360
Study: 26777745

Group type: EXPERIMENTAL
Intervention: Microbial cell preparation (treatment)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study: 23842100

Group type: EXPERIMENTAL
Intervention: Intravitreal FCFD4514S (maximum tolerated dose: 10 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravitreal FCFD4514S
Number of subjects: 18
Study: 21732501

Group type: EXPERIMENTAL
Intervention: Individual Family Work (IFW)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Multi-family workshops
Number of subjects: 23
Study: 20605216

Group type: EXPERIMENTAL
Intervention: Visante optical coherence tomography (OCT) TMH measurement
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: OCT lower TMH measurement
Number of subjects: 24
Study: 18685538

Group type: COMPARATOR
Intervention: Aerobic training (AT) alone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined aerobic training and resistance training (AT/RT1) - 1 set
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined aerobic training and resistance training (AT/RT3) - 3 sets
Number of subjects: 72
Study: 15639065

Group type: EXPERIMENTAL
Intervention: Cerazette (75-microg desogestrel-only contraceptive pill) taken for 56 days with three tablets taken 12 hours late
Number of subjects: 103
Study: 12788993

Group type: EXPERIMENTAL
Intervention: Intensive diabetes treatment
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Conventional diabetes treatment
Number of subjects: 1229
Study: 10793299

Group type: EXPERIMENTAL
Intervention: A cocktail of daily doses of 6 g of aged garlic extract, 4-6 g of vitamin C, and 800 to 1200 IU of vitamin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional antioxidant supplements, hydroxyl radical scavengers, and iron‐binding agents
Number of subjects: 0
Study: 8829945

Group type: EXPERIMENTAL
Intervention: Orbicularis oculi response (group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adductor pollicis response (group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 min wait (group 3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4 min wait (group 4)
Number of subjects: 120
Study: 2072407

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 3538

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus tamoxifen (30 mg daily for 48 weeks)
Number of subjects: 3538

Group type: COMPARATOR
Intervention: High-risk group not treated with tamoxifen
Number of subjects: 3538
Study: 6849755

Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone (Solu‐Medrol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 4 mg naloxone (Nalonee)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 6
Study: 31420399

Group type: EXPERIMENTAL
Intervention: SensiumVitals monitoring system (wearable wireless patch)
Number of subjects: 51
Study: 27586837

Group type: COMPARATOR
Intervention: Control (1.8 g leucine, n = 7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Leucine (3.5 g leucine, n = 8)
Number of subjects: 15
Study: 26850813

Group type: EXPERIMENTAL
Intervention: Polyherbal mouthwash (5% v/w)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 60
Study: 24182692

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone (T) @40 mg/ml, 1.5 ml, injections every three weeks until complete flattening or eight sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intralesional verapamil (V) @2.5 mg/ml, 1.5 ml, injections every three weeks until complete flattening or eight sessions
Number of subjects: 40
Study: 22524295

Group type: EXPERIMENTAL
Intervention: Negative mood induction (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neutral mood induction (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 30
Study: 20082701

Group type: EXPERIMENTAL
Intervention: Computer simulated heart sounds
Number of subjects: 14

Group type: COMPARATOR
Intervention: Additional bedside training
Number of subjects: 14
Study: 17391154

Group type: EXPERIMENTAL
Intervention: NN344 (0.8, 1.6, 2.8 DU/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Insulin detemir (0.4, 0.8, 1.4 U/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Insulin glargine (0.4, 0.8, 1.4 U/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: NN344 and insulin detemir
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: All insulin preparations
Number of subjects: 27
Study: 16331866

Group type: EXPERIMENTAL
Intervention: Resistance training only (n = 13)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Flexibility training only (n = 11)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Resistance and flexibility training (n = 9)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No intervention (control group) (n = 10)
Number of subjects: 43
Study: 12025879

Group type: EXPERIMENTAL
Intervention: VR group (using head-mounted display and position sensor)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-VR group (no specific details on intervention)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (received no special treatment)
Number of subjects: 30
Study: 11490526

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentamidine isethionate
Number of subjects: 0
Study: 7621730

Group type: EXPERIMENTAL
Intervention: Aspiration of insulin syringe during injection
Number of subjects: 204

Group type: COMPARATOR
Intervention: Non-aspiration technique for insulin administration
Number of subjects: 204
Study: 2883055

Group type: EXPERIMENTAL
Intervention: Pulsatile insulin (0.85 mU X kg‐1 X min‐1 during 2 min followed by 8 min with no insulin)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous insulin (0.17 mU X kg‐1 X min‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pulsatile insulin
Number of subjects: 6
Study: 29510979

Group type: EXPERIMENTAL
Intervention: Virtual-reality group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Paper-based group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study: 26876240

Group type: EXPERIMENTAL
Intervention: Combined orbital radiotherapy and steroid pulse therapy (SRT group)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Steroid pulse therapy only (ST group)
Number of subjects: 127
Study: 24961903

Group type: EXPERIMENTAL
Intervention: Audiovisual stimuli with different temporal intervals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 23135976

Group type: EXPERIMENTAL
Intervention: BIS-guided anaesthesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Routine anaesthesia care (non BIS-guided group)
Number of subjects: 45
Study: 20551485

Group type: EXPERIMENTAL
Intervention: Walking group (W, n = 14)
Number of subjects: 22
Study: 18845407

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Estriol
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Promestriene
Number of subjects: 41
Study: 19422676

Group type: EXPERIMENTAL
Intervention: Fentanyl (switched from buprenorphine)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Buprenorphine (switched from fentanyl)
Number of subjects: 32
Study: 15240609

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (crossover to Alendronate at 12 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 11816513

Group type: EXPERIMENTAL
Intervention: AN69 membranes (Group I)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cuprophane membranes (Group II)
Number of subjects: 25
Study: 9240727

Group type: EXPERIMENTAL
Intervention: 800 mg clodronate tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg clodronate capsule
Number of subjects: 0
Study: 8305996

Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (1 to 2 min)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Early umbilical cord clamping (immediate after delivery)
Number of subjects: 86
Study: 2880804

Group type: EXPERIMENTAL
Intervention: ICI 118551, 50 mg t.i.d. orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol, 80 mg t.i.d.
Number of subjects: 0
Study: 10657404

Group type: EXPERIMENTAL
Intervention: Selfotel (1.5 mg/kg intravenous dose within 6 hours of stroke onset)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 567
Study: 31615192

Group type: EXPERIMENTAL
Intervention: Motor imagery exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (neutral activities)
Number of subjects: 24
Study: 29538368

Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium longum subsp. infantis CECT7210)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control (no probiotic)
Number of subjects: 190
Study: 26897029

Group type: EXPERIMENTAL
Intervention: BBaRTS intervention (children's storybooks with embedded BCTs, parenting skills, and oral health messages)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: BBaRTS intervention supplemented with home supply of fluoride toothpaste (1000 ppmF) and supervised toothbrushing on schooldays
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Active Control (series of eight books with the same stories, characters, and illustrations but without BCTs, dental health messages, or parenting skills)
Number of subjects: 2000
Study: 24469161

Group type: EXPERIMENTAL
Intervention: Depressor septi nasi muscle excision through a transfixion incision
Number of subjects: 100

Group type: COMPARATOR
Intervention: Depressor septi nasi muscle transposition through an upper labial sulcus incision
Number of subjects: 100
Study: 23227315

Group type: EXPERIMENTAL
Intervention: Higher percentage body fat
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Higher fitness
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Fit women categorized as fat
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Obesity defined as ≥25 kg/m²
Number of subjects: 289
Study: 21060724

Group type: EXPERIMENTAL
Intervention: 5-Loxin(®) 100 mg daily for 90 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aflapin(®) 100 mg daily for 90 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17936736

Group type: EXPERIMENTAL
Intervention: 100 mg hydrocortisone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15167206

Group type: EXPERIMENTAL
Intervention: Constant drinkers consuming 0.1‐19.9 g alcohol per day
Number of subjects: 2710

Group type: EXPERIMENTAL
Intervention: Constant drinkers consuming 20.0‐39.9 g alcohol per day
Number of subjects: 2710

Group type: EXPERIMENTAL
Intervention: Female constant drinkers consuming 0.1‐19.9 g daily alcohol
Number of subjects: 2710
Study: 12269681

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (nonspecific foot massage)
Number of subjects: 76
Study: 9693202

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. + Amoxicillin 500 mg q.i.d. + Clarithromycin 400 mg b.i.d. (OAC)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.i.d. + Clarithromycin 400 mg b.i.d. (OC)
Number of subjects: 234
Study: 8207292

Group type: EXPERIMENTAL
Intervention: SY5555 150 mg x 3/day for 7 days
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SY5555 300 mg x 3/day for 7 days
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall efficacy for both dosages
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SY5555 150 mg x 3/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SY5555 300 mg x 3/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SY5555 treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SY5555
Number of subjects: 38
Study: 2734323

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30292578

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (Control)
Number of subjects: 86
Study: 28939581

Group type: EXPERIMENTAL
Intervention: VZV vaccination (live-attenuated VZVOka vaccine)
Number of subjects: 44
Study: 25416522

Group type: EXPERIMENTAL
Intervention: iPad (active distraction)
Number of subjects: 39

Group type: COMPARATOR
Intervention: AV glasses (passive distraction)
Number of subjects: 39
Study: 24146455

Group type: EXPERIMENTAL
Intervention: Cappra(®)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 21685235

Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg/d) for three weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 60
Study: 18085743

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (MTX)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 525
Study: 16487220

Group type: EXPERIMENTAL
Intervention: TDS-testosterone (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Androgel (1% topical testosterone gel)
Number of subjects: 12

Group type: COMPARATOR
Intervention: TDS-placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TDS-testosterone and Androgel
Number of subjects: 12
Study: 12066421

Group type: EXPERIMENTAL
Intervention: Fictitious medication with varying sample sizes (4, 6, 8, or 40 trials) and contingency (delta P = .20, .40, .60, or .80)
Number of subjects: 30
Study: 10321913

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 50 microg/day
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 75 microg/day
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 100 microg/day
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (all doses)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 8621845

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS), 4 mg inhaled, 4 times daily for 3 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo, 4 times daily for 3 months
Number of subjects: 26
Study: 1774443

Group type: EXPERIMENTAL
Intervention: Parlodel LAR (long-acting intramuscularly injectable depot preparation of bromocriptine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Parlodel LAR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Parlodel LAR and Placebo
Number of subjects: 20
Study: 7048890

Group type: EXPERIMENTAL
Intervention: Fructose sweetened cakes and ice creams
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ice creams
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sucrose sweetened cakes and ice creams
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cakes
Number of subjects: 26
Study: 30239596

Group type: EXPERIMENTAL
Intervention: Panfacial aesthetic treatment
Number of subjects: 2000
Study: 28967495

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (mock LLLT)
Number of subjects: 36
Study: 26088885

Group type: EXPERIMENTAL
Intervention: Lorazepam + Phenytoin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lorazepam + Valproate
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lorazepam + Levetiracetam
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall treatment (Lorazepam + 1st AED)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall treatment (with addition of 2nd AED)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall treatment (with addition of 3rd AED)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mortality within 1 month
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 150
Study: 24862386

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry with silicone hydrogel contact lens
Number of subjects: 28

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry without silicone hydrogel contact lens
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Comparison of both measurements
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bland-Altman analysis
Number of subjects: 28
Study: 22472294

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study: 19717942

Group type: EXPERIMENTAL
Intervention: Intermittent ultrasound (group 1, n=20)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo ultrasound (group 2, n=16)
Number of subjects: 36
Study: 17689931

Group type: EXPERIMENTAL
Intervention: Effective rTMS (10 Hz, 110% of motor threshold intensity, 15 sessions)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham rTMS (ineffective treatment)
Number of subjects: 22
Study: 15077097

Group type: EXPERIMENTAL
Intervention: Monteplase (1,600,000 IU IV), n = 19
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nontreatment group, n = 20
Number of subjects: 39
Study: 11354297

Group type: EXPERIMENTAL
Intervention: Rheohemapheresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional hemorheotherapy
Number of subjects: 0